Long-term outcome of treating rheumatoid arthritis: results after 20 years
- PMID: 2883443
- DOI: 10.1016/s0140-6736(87)91672-2
Long-term outcome of treating rheumatoid arthritis: results after 20 years
Abstract
Outcome of therapy, in terms of functional capacity, radiological measures of joint damage, erythrocyte sedimentation rate (ESR), rheumatoid factor, and mortality, was determined prospectively in 112 consecutive rheumatoid arthritis (RA) patients treated for 20 years at one centre, where a policy of active treatment was pursued with the use of gold, chloroquine, steroids, and, in resistant cases, penicillamine or cytotoxic drugs. By 20 years 35% were dead. Mortality was often attributable to RA. Function improved in the early years of treatment but declined considerably between 10 and 20 years. At 20 years 19% were severely disabled. Radiographs showed related evidence of increasing joint destruction. The ESR and rheumatoid factor levels changed little. Age, late presentation, and rheumatoid factor seropositivity at presentation were poor prognostic factors. The concept of "remission-inducing" drugs is fallacious. Early treatment may be advantageous, but the prognosis of RA is not good.
Similar articles
-
A 10 year prospective followup of patients with rheumatoid arthritis 1986-96.J Rheumatol. 2001 Nov;28(11):2409-15. J Rheumatol. 2001. PMID: 11708411
-
Is it possible to predict radiological damage in early rheumatoid arthritis (RA)? A report on the occurrence, progression, and prognostic factors of radiological erosions over the first 3 years in 866 patients from the Early RA Study (ERAS).J Rheumatol Suppl. 2004 Mar;69:48-54. J Rheumatol Suppl. 2004. PMID: 15053454
-
Longterm combination therapy of refractory and destructive rheumatoid arthritis with methotrexate (MTX) and intramuscular gold or other disease modifying antirheumatic drugs compared to MTX monotherapy.J Rheumatol. 1998 Aug;25(8):1485-92. J Rheumatol. 1998. PMID: 9712088 Clinical Trial.
-
Assessing prognosis and prediction of treatment response in early rheumatoid arthritis: systematic reviews.Health Technol Assess. 2018 Nov;22(66):1-294. doi: 10.3310/hta22660. Health Technol Assess. 2018. PMID: 30501821 Free PMC article.
-
Remission-inducing drugs in rheumatoid arthritis.Can Med Assoc J. 1980 Feb 23;122(4):405-15. Can Med Assoc J. 1980. PMID: 6768438 Free PMC article. Review.
Cited by
-
A five-year model to assess the early cost-effectiveness of new diagnostic tests in the early diagnosis of rheumatoid arthritis.Arthritis Res Ther. 2016 Jun 10;18(1):135. doi: 10.1186/s13075-016-1020-3. Arthritis Res Ther. 2016. PMID: 27287375 Free PMC article.
-
A contrasting view on rheumatoid arthritis.Am J Public Health. 1989 Sep;79(9):1308. doi: 10.2105/ajph.79.9.1308. Am J Public Health. 1989. PMID: 2764217 Free PMC article. No abstract available.
-
Unmet needs in rheumatoid arthritis.Arthritis Res Ther. 2005;7 Suppl 3(Suppl 3):S2-8. doi: 10.1186/ar1736. Epub 2005 May 18. Arthritis Res Ther. 2005. PMID: 15960819 Free PMC article. Review.
-
Inflammasomes in the pathophysiology of autoinflammatory syndromes.J Leukoc Biol. 2020 Mar;107(3):379-391. doi: 10.1002/JLB.3MIR0919-191R. Epub 2019 Oct 14. J Leukoc Biol. 2020. PMID: 31608507 Free PMC article. Review.
-
New therapeutic targets for rheumatoid arthritis.Pharm World Sci. 1999 Apr;21(2):49-59. doi: 10.1023/a:1008661630718. Pharm World Sci. 1999. PMID: 10380231 Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous